Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

ClinicalTrials.gov ID: NCT02166476

Public ClinicalTrials.gov record NCT02166476. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Study identification

NCT ID: NCT02166476
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Enrollment: 550 participants

Conditions and interventions

Conditions

Interventions

Meropenem-Vaborbactam Drug
Piperacillin-Tazobactam Drug
Levofloxacin Drug
Saline Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 19, 2014
Primary completion: Apr 27, 2016
Completion: Apr 27, 2016
Last update posted: Jun 10, 2018

2014 – 2016

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Not listed	Mobile	Alabama	36608	—
Not listed	San Diego	California	92120	—
Not listed	Denver	Colorado	80246	—
Not listed	Tampa	Florida	33606	—
Not listed	Augusta	Georgia	30912	—
Not listed	Chicago	Illinois	60612	—
Not listed	New Brunswick	New Jersey	08901	—
Not listed	Buffalo	New York	14215	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02166476, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 10, 2018 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02166476 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →